highperformr logo

Checkmate Pharmaceuticals's Overview

Total employees11
HeadquartersCambridge
Founded

Checkmate Pharmaceuticals was a clinical-stage biopharmaceutical company dedicated to developing proprietary oligonucleotides to activate the innate immune system and harness its power to combat cancer. Their leading product candidate, vidutolimod (CMP-001), a Toll-like receptor 9 (TLR9) agonist delivered as a biologic virus-like particle (VLP), aimed to sensitize tumors to checkpoint inhibitors and other cancer therapies by triggering a robust anti-tumor T cell response. In May 2022, Checkmate Pharmaceuticals was acquired by Regeneron Pharmaceuticals, integrating its promising assets into Regeneron's oncology portfolio.

Where is Checkmate Pharmaceuticals's Headquarters?

HQ Function

The Cambridge headquarters served as the central nexus for all company operations, including research and development, clinical trial management, corporate strategy, and administrative functions.

Notable Features:

Located within the Kendall Square area, known for its high concentration of life science companies and research institutions, providing access to state-of-the-art facilities and a rich talent ecosystem.

Work Culture:

Characterized by a scientifically driven, innovative, and collaborative environment, with a strong focus on a patient-centric mission to develop transformative cancer therapies. It was likely a dynamic and fast-paced setting typical of clinical-stage biotech firms.

HQ Significance:

The Cambridge location was strategically important, offering proximity to leading academic research, potential collaborators, and a skilled workforce, crucial for a company in the competitive field of cancer immunotherapy.

Values Reflected in HQ: The headquarters embodied values of scientific excellence, innovation, urgency in addressing patient needs, and collaboration within the broader life sciences community.

Location:

As a clinical-stage biopharmaceutical company, Checkmate Pharmaceuticals's global presence was primarily manifested through its international clinical trial sites and collaborations. While its operational hub was in the United States, the development of its oncology pipeline, particularly vidutolimod, involved engaging with investigators, research institutions, and patient populations across multiple countries. Following its acquisition, its assets contribute to Regeneron's established global operational and commercial footprint.

Street Address:

245 Main Street, Suite 500

City:

Cambridge

State/Province:

Massachusetts

Country:

USA

Checkmate Pharmaceuticals's Global Presence

N/A

Address: N/A

All core corporate, research, and development operations were largely consolidated at the main headquarters to ensure cohesive strategy and execution.

Buying Intent Signals for Checkmate Pharmaceuticals

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Checkmate Pharmaceuticals

As of April 2025, Checkmate Pharmaceuticals' leadership includes:

Barry Labinger - Former President and Chief Executive Officer
Arthur M. Krieg, MD - Founder and Former Chief Scientific Officer
Robert F. Dolski - Former Chief Financial Officer
Kleem Chaudhary, Ph.D. - Former Chief Business Officer
Keith L. Olson - Former Chief Operating Officer
Karen L. Ferrante, M.D. - Former Chief Medical Officer

Investors of Checkmate Pharmaceuticals

Checkmate Pharmaceuticals has been backed by several prominent investors over the years, including:

Sofinnova Investments
venBio Partners
F-Prime Capital
Omega Funds
Decheng Capital
Medicxi
Longwood Fund
Regeneron Pharmaceuticals (Acquirer)

Executive New Hires/Exits in the Last 12 Months

Hire0
Exits6

The most significant executive event for Checkmate Pharmaceuticals was its acquisition by Regeneron Pharmaceuticals in May 2022. This event led to the transition of its entire executive leadership team as the company was integrated into Regeneron. There were no major publicly announced new hires to the independent Checkmate executive team in the 12 months leading up to the acquisition.

Departures

Barry Labinger, Departed role following Regeneron's acquisition of Checkmate Pharmaceuticals.
Arthur M. Krieg, MD, Departed role following Regeneron's acquisition.
Robert F. Dolski, Departed role following Regeneron's acquisition.
Kleem Chaudhary, Ph.D., Departed role following Regeneron's acquisition.
Keith L. Olson, Departed role following Regeneron's acquisition.
Karen L. Ferrante, M.D., Departed role following Regeneron's acquisition.

Technology (Tech Stack) used by Checkmate Pharmaceuticals

Discover the tools Checkmate Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Checkmate Pharmaceuticals Email Formats and Examples

Prior to its acquisition by Regeneron, Checkmate Pharmaceuticals likely utilized standard corporate email formats. Common structures include [first_initial][last]@[companydomain.com] or [first].[last]@[companydomain.com]. These formats are provided for historical reference as the checkmatepharma.com domain is no longer active for email.

[first_initial][last]@checkmatepharma.com or [first].[last]@checkmatepharma.com

Format

jdoe@checkmatepharma.com

Example

0%

Success rate

News and media

Regeneron PharmaceuticalsMay 19, 2022

Regeneron Completes Acquisition of Checkmate Pharmaceuticals

Regeneron Pharmaceuticals, Inc. announced the successful completion of its acquisition of Checkmate Pharmaceuticals, Inc. This acquisition brings Checkmate's expertise in harnessing the immune system to combat cancer, notably its lead candidate vidutolimod, into Regeneron's portfolio....more

GlobeNewswire (PR Newswire)April 19, 2022

Regeneron to Acquire Checkmate Pharmaceuticals to Advance New Frontier of Immunotherapies for Hard-to-Treat Cancers

Regeneron Pharmaceuticals and Checkmate Pharmaceuticals announced a definitive agreement for Regeneron to acquire Checkmate for $10.50 per share in cash. The acquisition aimed to add Checkmate's vidutolimod, an investigational TLR9 agonist, to Regeneron's growing oncology pipeline....more

GlobeNewswireMarch 1, 2022

Checkmate Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights

Checkmate Pharmaceuticals reported its financial results for Q4 and full-year 2021, providing updates on its clinical programs, including ongoing trials for vidutolimod in melanoma and non-small cell lung cancer, and outlining its strategic priorities for advancing its pipeline....more

GlobeNewswireNovember 9, 2021

Checkmate Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Checkmate Pharmaceuticals announced its Q3 2021 financial results and provided an update on its clinical development programs, emphasizing the progress of vidutolimod (CMP-001) in combination therapies for various cancers....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Checkmate Pharmaceuticals, are just a search away.